Trial Profile

Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cangrelor (Primary) ; Prasugrel (Primary) ; Tirofiban (Primary) ; Aspirin; Aspirin
Indications Cardiovascular disorders; Coronary artery disease; Myocardial infarction; Stroke; Thrombosis; Transient ischaemic attacks
Focus Pharmacodynamics
Acronyms FABOLUS-FASTER

04 Aug 2020 Primary endpoint has been met. (Inhibition of platelet activity (IPA, %) with LTA-ADP 20 mol/l)
04 Aug 2020 Results published in the Circulation
29 Jun 2020 According to a Medicure media release, results from this study were recently presented virtually at the PCR e-Course Scientific Sessions, due to the cancellation of EuroPCR 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com